OAM
AMLX icon

Oxford Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Oxford Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,120
Closed -$260K – 488
2025
Q3 		$260K Buy
+19,120
New +$180K 0.09% 360

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Oxford Asset Management's AMLX Position: Q4 2025 in Review

Oxford Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 19,120 shares — an estimated $260K sold.

Oxford Asset Management first reported a position in AMLX in Q3 2025 and held it in 1 quarter. The position peaked at $260K in Q3 2025. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Oxford Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 19,120 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $260K.
  • Oxford Asset Management first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Oxford Asset Management's Amylyx Pharmaceuticals position peaked at $260K in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.